EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.
about
Recent advancements in multimodality treatment of gliomasPhase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.Molecular targeting of glioblastoma: Drug discovery and therapiesExperimental approaches for the treatment of malignant gliomas.Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approachesAntiangiogenic therapy for glioblastoma: current status and future prospects.The challenges and the promise of molecular targeted therapy in malignant gliomas.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.The VEGF pathway in cancer and disease: responses, resistance, and the path forward.Combining molecular targeted agents with radiation therapy for malignant gliomasRecurrence patterns in patients with high-grade glioma following temozolomide-based chemoradiotherapy.An update in the use of antibodies to treat glioblastoma multiforme.Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study.Lumbar puncture-administered resveratrol inhibits STAT3 activation, enhancing autophagy and apoptosis in orthotopic rat glioblastomas.Current and emerging molecular targets in glioma.Antiangiogenic therapies in glioblastoma multiforme.Animal models for glioma drug discovery.Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach.Targeted therapy in gliomas.Current role of anti-angiogenic strategies for glioblastoma.Receptor tyrosine kinase inhibitors: Are they real tumor killers?Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival.SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.Anti-angiogenic therapy in high-grade glioma (treatment and toxicity).Neovascularization in Glioblastoma: Current Pitfall in Anti-angiogenic therapy.American Association for Cancer Research Genetics and Biology of Brain Cancers 2009, December 13-15, 2009, San Diego, CA.Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target.(1) H 2D MRSI tissue type analysis of gliomas.Pattern of relapse of glioblastoma multiforme treated with radical radio-chemotherapy: Could a margin reduction be proposed?A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma.
P2860
Q27001724-4CC730C9-DFDF-497E-AB11-5BD165B6D3DAQ33391770-65847043-7926-4F74-9F2C-A74B4E90883AQ33403967-B645ED31-6CFE-4315-811B-238B71807E5EQ33911283-5E2E53B1-9452-4DED-8D08-633BADA55375Q34127138-3D270A90-E068-4529-97F5-3576B2D0F8B4Q34515465-D866A5FF-B437-462C-846C-930028BE0FF2Q34523319-765589F5-A24D-4236-A27C-7E8E8DADF767Q35214534-8BE25966-4161-4063-88EB-4E5B6FD4F1CBQ35895174-05DEA3EB-8FE6-45D2-9830-A6F97A33246EQ36103026-CECA4446-FA9E-420E-BB80-DCF6CA138015Q36526512-766949C8-2FDF-41A3-906C-668BD522C088Q37099594-129E9C82-F85F-400E-B56A-DFAE3EE6DF63Q37108692-7DDEB375-AE22-4935-93BD-7410EBC07CBAQ37329927-AB673070-567A-4EA4-B89D-921CDF7A4232Q37474359-566DA109-EB2D-490C-9782-FCC2F5A1B5B5Q37689021-40438651-DE5B-495B-8EF8-3B6F0B7769D6Q37809861-E60FCB3C-8955-4415-86EF-1890917E3EE8Q38010802-FA696594-D8D7-4E06-8779-84D635368A10Q38014575-8017192F-3D14-4E47-B120-8B79761E68DCQ38108186-45935910-06D5-41C7-BE9C-D2ABD1EFED0FQ38186656-957C3CB3-2324-45D6-B19C-7F41B56232A2Q38244844-B9E1E58C-E526-4BE0-A9F2-23F6E84711B9Q38365290-86E17B74-FBE9-4710-A8D3-01AA7F2526BDQ38480274-2A1CDBEA-98EB-40DE-A656-AC46663EE5FFQ39521060-EABF0DE0-A9D0-4493-9E16-5CE5715A10E0Q40705444-7C126C71-18C6-4F53-93C0-8BDEF0028CF3Q41383985-5B35AC97-2D01-4D59-BA32-147C0BB83DA5Q42529944-13E4A32E-50D5-4D33-BC23-ABA1669091E2Q42573750-47CDCF07-CEC9-4DF9-BAFC-D17D1DE6A181Q48737714-C87B85E1-7853-480F-AE13-59165D6EB437Q52143325-7C18C673-5F47-408C-B064-AE663BE425D5Q55001435-2CB5C269-66F8-439C-AFFC-CC60FE3061B2
P2860
EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
EORTC study 26041-22041: phase ...... newly diagnosed glioblastoma.
@ast
EORTC study 26041-22041: phase ...... newly diagnosed glioblastoma.
@en
type
label
EORTC study 26041-22041: phase ...... newly diagnosed glioblastoma.
@ast
EORTC study 26041-22041: phase ...... newly diagnosed glioblastoma.
@en
prefLabel
EORTC study 26041-22041: phase ...... newly diagnosed glioblastoma.
@ast
EORTC study 26041-22041: phase ...... newly diagnosed glioblastoma.
@en
P2093
P1476
EORTC study 26041-22041: phase ...... newly diagnosed glioblastoma.
@en
P2093
Alicia Tosoni
Denis Lacombe
Johan M Kros
Martin J van den Bent
Renè O Mirimanoff
Roger Stupp
Thierry Gorlia
P304
P356
10.1016/J.EJCA.2009.10.029
P577
2009-11-27T00:00:00Z